title: Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats.
abstract: Fluoxetine (Prozac), an antidepressant known to selectively inhibit serotonin reuptake, is widely used to treat mood disorders in women suffering from depression during pregnancy and postpartum period. Several lines of evidence suggest that this drug, which crosses the human placenta and is secreted into milk during lactation, exerts its action not only by interfering with serotoninergic but also with GABAergic transmission. GABA is known to play a crucial role in the construction of neuronal circuits early in postnatal development. The immature hippocampus is characterized by an early type of network activity, the so-called Giant Depolarizing Potentials (GDPs), generated by the synergistic action of glutamate and GABA, both depolarizing and excitatory. Here we tested the hypothesis that fluoxetine may interfere with GABAergic signaling during the first postnatal week, thus producing harmful effects on brain development. At micromolar concentrations fluoxetine severely depressed GDPs frequency (IC50 22 μM) in a reversible manner and independently of its action on serotonin reuptake. This effect was dependent on a reduced GABAergic (but not glutamatergic) drive to principal cells most probably from parvalbumin-positive fast spiking neurons. Cholecystokinin-positive GABAergic interneurons were not involved since the effects of the drug persisted when cannabinoid receptors were occluded with WIN55,212-2, a CB1/CB2 receptor agonist. Fluoxetine effects on GABAergic transmission were associated with a reduced firing rate of both principal cells and interneurons further suggesting that changes in network excitability account for GDPs disruption. This may have critical consequences on the functional organization and stabilization of neuronal circuits early in postnatal development.
authors: Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati Trieste, Italy.
authors: Maddalena D
authors: MD
authors: Caiati
authors: Enrico
authors: E
authors: Cherubini
keywords: GDPs; fluoxetine; immature hippocampus; spontaneous action potential-dependent release of GABA; spontaneous firing of principal cells and interneurons
references: Mol Pharmacol. 2006 Dec;70(6):2052-63
references: 16985186
references: Breastfeed Med. 2011 Apr;6(2):89-98
references: 20958101
references: Neuron. 2007 Oct 4;56(1):33-42
references: 17920013
references: Neuroscientist. 2012 Oct;18(5):467-86
references: 22547529
references: Life Sci. 1974 Aug 1;15(3):471-9
references: 4549929
references: Life Sci. 1995;57(5):411-41
references: 7623609
references: Science. 2008 Jul 4;321(5885):53-7
references: 18599766
references: J Neurochem. 2010 Aug;114(3):697-705
references: 20477941
references: Science. 2009 Dec 4;326(5958):1419-24
references: 19965761
references: Neuropsychopharmacology. 2005 Aug;30(8):1576-83
references: 15886723
references: Curr Opin Neurobiol. 2011 Feb;21(1):160-8
references: 21074988
references: Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3967-72
references: 15007179
references: Neuron. 2011 Aug 25;71(4):695-709
references: 21867885
references: Neuropharmacology. 2003 Oct;45(5):661-71
references: 12941379
references: Epilepsy Res. 2012 Aug;101(1-2):174-81
references: 22520760
references: Neuropharmacology. 2000 Apr 3;39(6):1029-36
references: 10727713
references: Neuroscience. 2012 Sep 18;220:131-41
references: 22728102
references: Eur J Neurosci. 1998 Mar;10(3):899-906
references: 9753157
references: Clin Pharmacol Ther. 2009 Dec;86(6):672-7
references: 19890255
references: Eur J Neurosci. 2011 Jan;33(1):49-57
references: 21156002
references: J Neurosci. 2008 Jun 11;28(24):6272-80
references: 18550770
references: Nat Rev Neurosci. 2005 Mar;6(3):241-6
references: 15738959
references: J Neurosci. 2005 Jun 1;25(22):5280-9
references: 15930375
references: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 1;35(6):1400-8
references: 20883714
references: J Physiol. 1989 Sep;416:303-25
references: 2575165
references: Am J Psychiatry. 2002 Nov;159(11):1889-95
references: 12411224
references: Nature. 2008 Oct 16;455(7215):894-902
references: 18923511
references: J Physiol. 2007 Jun 1;581(Pt 2):515-28
references: 17317750
references: Eur J Pharmacol. 1996 Sep 5;311(1):1-6
references: 8884229
references: Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13176-81
references: 17656555
references: Neuron. 2006 Jan 5;49(1):131-42
references: 16387645
references: J Physiol. 2012 Oct 1;590(19):4777-87
references: 22674715
references: J Pharmacol Exp Ther. 2003 Mar;304(3):978-84
references: 12604672
references: Science. 2008 Apr 18;320(5874):385-8
references: 18420937
references: J Physiol. 2008 Nov 15;586(22):5437-53
references: 18801845
references: Expert Rev Neurother. 2010 May;10(5):645-9
references: 20420486
references: J Neuropsychiatry Clin Neurosci. 1993 Summer;5(3):322-9
references: 8369643
references: J Neurosci. 2010 Feb 3;30(5):1750-9
references: 20130184
references: Sci Rep. 2012;2:285
references: 22368777
references: BJOG. 2002 Sep;109(9):1003-8
references: 12269673
references: J Neurosci. 2012 May 9;32(19):6688-98
references: 22573691
references: Mol Psychiatry. 2011 Apr;16(4):383-406
references: 21079608
references: Mol Pharmacol. 2006 Jun;69(6):1963-8
references: 16510561
references: J Neurophysiol. 1999 May;81(5):2095-102
references: 10322051
references: Trends Neurosci. 1991 Dec;14(12):515-9
references: 1726341
references: Science. 2002 Jun 14;296(5575):2049-52
references: 12065842
references: Br J Pharmacol. 1999 Dec;128(7):1609-15
references: 10602343
references: Psychopharmacology (Berl). 2011 Oct;217(3):419-32
references: 21487650
references: J Cell Sci. 2003 Apr 1;116(Pt 7):1209-17
references: 12615964
references: J Neurosci. 2012 Nov 21;32(47):16616-28
references: 23175817